Paul Rennie, MBM, MSTC
Non-executive Chairman

Experienced biotechnology executive with extensive sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Founder and CEO of Paradigm Biopharmaceuticals (ASX:PAR). Inaugural COO and Executive VP, New Product Development at Mesoblast (ASX:MSB).

Stephen Quantrill, MBA
Non-Executive Director

With over 20 years’ experience in corporate advisory and company directorship, Mr Quantrill is also the Executive Chairman of McRae Investments, family-owned investment and venture capital company created by successful Australian businessman Dr. Harold Clough AO, OBE. Stephen is currently a director of several McRae's investee public and private companies.

Dr Anton Uvarov, PhD, MBA
Non-Executive Director

Founding director of Actinogen Medical (ASX:ACW) an advanced Alzheimer’s biotechnology company. Non-executive director at Nutritional Growth Solutions (ASX:NGS). Former Equities Analyst with Citigroup, US and former director at Dimerix (ASX:DXB) and Imugene (ASX:IMU).

Dougal Thring, MPharmMed
VP of Clinical Development

Dougal has over 12 years of clinical trials experience, over 2 years in phase II to Phase IV Respiratory trials and an extensive 10 years’ experience in Phase I-II trials, with premier early phase clinical research provider, Linear Clinical Research Ltd, across multiple roles, most recently Head of Clinical Solutions ensuring clients were bringing trial designs that were scientifically appropriate, aligned with regulations, logistically sound and time efficient. Dougal additionally has been Early Phase Advisor for Delve Medical Writing and is a Guest Lecturer for UNSW’s Master of Pharmaceutical Medicine program. As part of the NeuroScientific executive team, Dougal oversees and manages the overall clinical development process, clinical strategy and regulatory operations of the company.

Abby Macnish Niven, CFA
Company Secretary & CFO

Abby Macnish is an investment professional with over 15 years experience. Currently, Abby works closely with the Executive Chair at McRae Investments, analysing transactions, managing investments and monitoring cash flows and financials. She is the CFO and Company Secretary for two listed companies, including NSB. Abby is also the Chair of the Investment Committee at TWD Australia and a board member for Muscular Dystrophy WA (MDWA), a charity with the aim of supporting the MDWA community. She has a Bachelors’ Degree in Science and Commerce from the University of Western Australia and is a Chartered Financial Analyst® (CFA) charterholder.

Clinical Professor Allan Kermode, MBBS, MD, FRACP, FRCP
Scientific Advisor

Clinical Professor Allan Kermode is a Consultant Neurologist and Head of the Demyelinating Diseases Research at the Perron Institute, Clinical Professor of Neurology at the University of Western Australia and Visiting Professor at Sun Yat Sen University, PR China. Former Head of the Department of Neurology and Clinical Neurophysiology at Sir Charles Gairdner Hospital. Previous appointments include Oxford University Dept of Neurology, Institute of Molecular Medicine, National Hospital for Neurology in London, UK, and National Institutes of Health, USA. Professor Kermode sees patients with multiple sclerosis (MS), manages a research team investigating causes of MS, and is Professor of Immunology at the Institute for Immunology and Infectious Diseases (IIID) based at Murdoch University, where he also conducts MS clinics.

Professor Dao-Yi Yu
Scientific Advisor

Head of Physiology & Pharmacology, Lions Eye Inst Clinical ophthalmologist with >25 years in ocular research. Lead inventor of numerous patents including a system for ocular ultrasurgery, ocular tonometer and biological microfistula. Appointments include Professor, Centre for Ophthalmology & Visual Science at UWA and Adjunct Professor, Dept. Ophthalmolgy & Visual Sciences at Dalhousie University of Medicine.

Dr Frank Bonner, PhD, BSc
Scientific Advisor

Dr Bonner has >35 years of experience in toxicology and non-clinical drug development, working for pharmaceutical (Senior Vice President, Sanofi), and contract research industries, in addition to 15 years as an independent consultant. He brings comprehensive knowledge across all aspects of regulatory guidance and advocacy and outsourced programme management. Dr Bonner has served as a Scientific Advisor for a number of technology and drug development SME’s and has Board level experience including Executive Director, Stem Cells for Safer Medicines; Non-Executive Chairman, Maccine Pte, Singapore; Executive Director, Life Science Research Inc. etc. He is a fellow of the British Toxicology Society, Past President of the Society and Visiting Professor in the Division of Integrative Systems Medicines at Imperial College, London.

Dr. Peter Hnik, MD, MHSc
Scientific Advisor

Dr Peter Hnik is an ophthalmologist with special interests including glaucoma and neuro-ophthalmology. He received his Medical Degree from Charles University in Prague and a Master of Health Science from the University of British Columbia, Canada. He served as Director and Chief Medical Officer at iCo Therapeutics Inc. and Associate Director of Clinical Research at QLT Inc. Dr Hnik is currently President of Clinscape Consulting Inc. where he specialises in designing preclinical packages and clinical programs across a range of ophthalmic and other indications. Dr Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), and the Drug Information Association (DIA).